Doximity (NYSE:DOCS) - Aandelenkoers, Nieuws & Analyse

DOCS Overzicht aandelen

Doximity, Inc. exploiteert een cloudgebaseerd digitaal platform voor medische professionals in de Verenigde Staten.

DOCS fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	1/6
Prestaties in het verleden	4/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Earnings are forecast to grow 5.87% per year

Earnings grew by 35.1% over the past year

Risicoanalyse

Volatile share price over the past 3 months compared to the US market

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion

Key Takeaways Accelerating adoption of new products and a client portal, alongside strategic positioning with top clients, suggests sustained revenue expansion. Record unique active user growth and introduction of HIPAA-compliant tools like Doximity GPT indicate increasing platform engagement and operational efficiencies.

View narrative

US$37.21

13.8% overvalued

8.31%

Revenue growth p.a.

4 days ago

Doximity, Inc. Concurrenten

Veeva Systems

NYSE:VEEV

US$34.5b

HealthStream

NasdaqGS:HSTM

US$892.1m

Simulations Plus

NasdaqGS:SLP

US$557.5m

Masimo

NasdaqGS:MASI

US$7.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Doximity
Historische aandelenkoersen
Huidige aandelenkoers	US$42.35
52 Week Hoogtepunt	US$44.88
52 Week Laag	US$20.28
Bèta	1.29
11 maand verandering	-3.38%
3 maanden verandering	61.33%
1 Jaar Verandering	98.83%
33 jaar verandering	-40.39%
5 jaar verandering	n/a
Verandering sinds IPO	-20.09%

Recent nieuws en updates

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Nov 02

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Oct 15

Doximity: Downgrade To Hold On Valuation Concerns

Oct 03

Recent updates

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Nov 02

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Aug 18

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

Aug 10

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Jul 23

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Jul 23

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Jul 01

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Jun 09

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

May 17

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

May 04

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Apr 29

With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Apr 16

Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Mar 26

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Feb 21

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

Feb 15

What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Feb 13

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Jan 16

Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Jan 04

Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price

Dec 14

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Nov 10

Doximity: Adding Value Using AI But Faces Near-Term Risks

Nov 01

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Oct 30

Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively

Sep 25

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Aug 24

Doximity Earnings: Too Many Problems, Sell

Aug 09

A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

Jul 29

Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching

Jul 09

Doximity: Continue To See Positive Upside From Current Stock Level

Jul 05

The Returns At Doximity (NYSE:DOCS) Aren't Growing

Jun 21

Doximity: Digital Health Play With Strong Fundamentals

Jun 21

A Look At The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Apr 07

Doximity (NYSE:DOCS) Is Reinvesting At Lower Rates Of Return

Mar 20

Doximity: Good Business But Extremely Overvalued

Feb 18

Doximity Q3 Earnings: Disappointing Results

Feb 10

Calculating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Dec 25

Doximity: On The Right Path To Further Consolidate Market Share

Dec 22

Here's What's Concerning About Doximity's (NYSE:DOCS) Returns On Capital

Dec 04

Rendement voor aandeelhouders

	DOCS	US Healthcare Services	US Markt
7D	2.2%	0.4%	-1.6%
1Y	98.8%	2.4%	30.8%

Rendement versus industrie: DOCS exceeded the US Healthcare Services industry which returned 2% over the past year.

Rendement versus markt: DOCS exceeded the US Market which returned 30.6% over the past year.

Prijsvolatiliteit

Is DOCS's price volatile compared to industry and market?
DOCS volatility
DOCS Average Weekly Movement	11.4%
Healthcare Services Industry Average Movement	8.8%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: DOCS's share price has been volatile over the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: DOCS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	827	Jeff Tangney	www.doximity.com

Doximity, Inc. exploiteert een cloudgebaseerd digitaal platform voor medische professionals in de Verenigde Staten. Het platform van het bedrijf biedt zijn leden digitale tools die gebouwd zijn voor de geneeskunde, waarmee zijn leden kunnen samenwerken met collega's, op de hoogte kunnen blijven van het laatste medische nieuws en onderzoek, hun carrière en oproepschema's kunnen beheren, documentatie en administratie kunnen stroomlijnen en virtuele patiëntbezoeken kunnen afleggen. Het bedient voornamelijk artsen, nurse practitioners, physician assistants, medische studenten, farmaceutische fabrikanten en gezondheidszorgsystemen.

Doximity, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Doximity zich tot de beurswaarde?
DOCS fundamentele statistieken
Marktkapitalisatie	US$7.86b
Inkomsten(TTM)	US$160.55m
Inkomsten(TTM)	US$493.63m

49.0x

Koers/Winstverhouding

15.9x

P/S-verhouding

Is DOCS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DOCS resultatenrekening (TTM)
Inkomsten	US$493.63m
Kosten van inkomsten	US$51.07m
Brutowinst	US$442.56m
Overige uitgaven	US$282.01m
Inkomsten	US$160.55m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 07, 2024

Winst per aandeel (EPS)	0.86
Brutomarge	89.66%
Nettowinstmarge	32.53%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde DOCS op de lange termijn?

Bekijk historische prestaties en vergelijking

DOCS Overzicht aandelen

Beloningen

Risicoanalyse

Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion

Doximity, Inc. Concurrenten

NYSE:VEEV

US$34.5b

NasdaqGS:HSTM

US$892.1m

NasdaqGS:SLP

US$557.5m

NasdaqGS:MASI

US$7.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Independent Director notifies of intention to sell stock

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Doximity, Inc. to Report Q2, 2025 Results on Nov 07, 2024

Price target increased by 8.5% to US$37.21

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity: Downgrade To Hold On Valuation Concerns

Recent updates

Independent Director notifies of intention to sell stock

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Doximity, Inc. to Report Q2, 2025 Results on Nov 07, 2024

Price target increased by 8.5% to US$37.21

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity: Downgrade To Hold On Valuation Concerns

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Now 22% overvalued after recent price rise

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Investor sentiment improves as stock rises 39%

Chief Financial Officer exercised options and sold US$1.1m worth of stock

Price target increased by 7.1% to US$31.64

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

New minor risk - Share price stability

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Revenue Guidance for the Second Quarter Ending September 30, 2024 and Fiscal Year Ending March 31, 2025

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Doximity, Inc., Annual General Meeting, Aug 29, 2024

Doximity, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Now 29% undervalued

Now 28% undervalued

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Now 22% undervalued after recent price drop

Chief Financial Officer notifies of intention to sell stock

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Doximity, Inc. Provides Financial Guidance for the First Quarter Ending June 30, 2024 and Full Year Ending March 31, 2025

Full year 2024 earnings released: EPS: US$0.78 (vs US$0.58 in FY 2023)

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $500 million worth of its shares.

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Doximity, Inc. to Report Q4, 2024 Results on May 16, 2024

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Doximity, Inc

With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending March 31, 2024

Price target increased by 7.2% to US$28.17

Doximity, Inc. to Report Q3, 2024 Results on Feb 08, 2024

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price

Now 21% undervalued

Investor sentiment improves as stock rises 24%

Doximity, Inc. Provides Revenue Guidance for the Fiscal Third Quarter Ending December 31, 2023 and Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $70 million worth of its shares.

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Doximity Launches Docdefender, Expanding Services to Safeguard Physician Privacy

Doximity: Adding Value Using AI But Faces Near-Term Risks

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity, Inc. to Report Q2, 2024 Results on Nov 09, 2023

Insufficient new directors